• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Discovery of -Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties.基于具有改善类药性质的α-烷基哌嗪侧链的CXCR4拮抗剂的发现。
ACS Med Chem Lett. 2018 Apr 9;9(5):446-451. doi: 10.1021/acsmedchemlett.8b00030. eCollection 2018 May 10.
2
Discovery of novel N-aryl piperazine CXCR4 antagonists.新型N-芳基哌嗪类CXCR4拮抗剂的发现
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4950-4955. doi: 10.1016/j.bmcl.2015.04.036. Epub 2015 Apr 17.
3
Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.新型四氢萘啶类 CXCR4 拮抗剂的合成与评价，改善药物样特性。
J Med Chem. 2022 Mar 10;65(5):4058-4084. doi: 10.1021/acs.jmedchem.1c01564. Epub 2022 Feb 18.
4
Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings.通过后期布赫瓦尔德偶联具有改善的药代动力学性质的氨基杂环四氢异喹啉CXCR4拮抗剂
ACS Med Chem Lett. 2021 Oct 4;12(10):1605-1612. doi: 10.1021/acsmedchemlett.1c00449. eCollection 2021 Oct 14.
5
Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.基于四氢异喹啉的CXCR4拮抗剂的发现。
ACS Med Chem Lett. 2013 Sep 5;4(11):1025-30. doi: 10.1021/ml400183q. eCollection 2013 Nov 14.
6
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.具有刚性侧链的新型四氢异喹啉CXCR4拮抗剂的合成
ACS Med Chem Lett. 2017 Dec 20;9(2):89-93. doi: 10.1021/acsmedchemlett.7b00406. eCollection 2018 Feb 8.
7
Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.发现含有四氢异喹啉的 CXCR4 拮抗剂，具有改善的体外 ADMET 性质。
J Med Chem. 2018 Feb 8;61(3):946-979. doi: 10.1021/acs.jmedchem.7b01420. Epub 2018 Jan 30.
8
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.基于第二代四氢异喹啉的 CXCR4 拮抗剂的设计、合成及药效学评价，具有良好的 ADME 性质。
J Med Chem. 2018 Aug 23;61(16):7168-7188. doi: 10.1021/acs.jmedchem.8b00450. Epub 2018 Aug 15.
9
Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.6-氨基烟酰胺磺酰脲类衍生物的合成、结构-性质关系及作为 P2Y₁₂ 受体拮抗剂的药代动力学评价。
Eur J Med Chem. 2013 Jul;65:360-75. doi: 10.1016/j.ejmech.2013.04.007. Epub 2013 May 15.
10
The metabolic stability of acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitors, N-(4-benzyloxy-3, 5-dimethoxycinnamoyl)-N'-(2, 4-dimethylphenyl)piperazine (YIC-708-424) and its derivatives in rat liver and intestinal epithelium.
Biol Pharm Bull. 2003 May;26(5):600-7. doi: 10.1248/bpb.26.600.

引用本文的文献

1
Ligand effect of cyclometallated iridium(iii) complexes on -alkylation of amines in hydrogen borrowing reactions.环金属化铱（III）配合物在氢转移反应中对胺的α-烷基化的配体效应
RSC Adv. 2023 Oct 31;13(45):31948-31961. doi: 10.1039/d3ra07184g. eCollection 2023 Oct 26.
2
Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes.设计靶向 I/IV 类溴结构域的染色质重塑复合物降解剂。
ACS Chem Biol. 2023 Jun 16;18(6):1278-1293. doi: 10.1021/acschembio.2c00902. Epub 2023 Jun 1.
3
At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.在实验台上：CXCR4 在癌症中的多种功能的临床前证据。
J Leukoc Biol. 2021 May;109(5):969-989. doi: 10.1002/JLB.2BT1018-715RR. Epub 2020 Oct 26.
4
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.发现强效和选择性表皮生长因子受体（EGFR）双功能小分子降解剂。
J Med Chem. 2020 Feb 13;63(3):1216-1232. doi: 10.1021/acs.jmedchem.9b01566. Epub 2020 Jan 14.
5
Combination of PET and CXCR4-Targeted Peptide Molecule Agents for Noninvasive Tumor Monitoring.PET与CXCR4靶向肽分子试剂联合用于无创肿瘤监测
J Cancer. 2019 Jun 9;10(15):3420-3426. doi: 10.7150/jca.31087. eCollection 2019.

本文引用的文献

1
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.具有刚性侧链的新型四氢异喹啉CXCR4拮抗剂的合成
ACS Med Chem Lett. 2017 Dec 20;9(2):89-93. doi: 10.1021/acsmedchemlett.7b00406. eCollection 2018 Feb 8.
2
Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.发现含有四氢异喹啉的 CXCR4 拮抗剂，具有改善的体外 ADMET 性质。
J Med Chem. 2018 Feb 8;61(3):946-979. doi: 10.1021/acs.jmedchem.7b01420. Epub 2018 Jan 30.
3
Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.基于四氢异喹啉的CXCR4拮抗剂的发现。
ACS Med Chem Lett. 2013 Sep 5;4(11):1025-30. doi: 10.1021/ml400183q. eCollection 2013 Nov 14.
4
Structural modifications that alter the P-glycoprotein efflux properties of compounds.改变化合物P-糖蛋白外排特性的结构修饰。
J Med Chem. 2012 Jun 14;55(11):4877-95. doi: 10.1021/jm201136z. Epub 2012 Apr 16.
5
Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).针对CXC趋化因子受体4（CXCR4）的药物发现研究。
J Med Chem. 2012 Feb 9;55(3):977-94. doi: 10.1021/jm200568c. Epub 2011 Dec 2.
6
Agonists for the Chemokine Receptor CXCR4.趋化因子受体CXCR4的激动剂
ACS Med Chem Lett. 2011 Aug 11;2(8):597-602. doi: 10.1021/ml200084n. Epub 2011 Jun 6.
7
Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression.成年小鼠 Cxcl12/Sdf-1 的缺失会降低造血干细胞/祖细胞的静止状态，并改变骨髓抑制后造血再生的模式。
Blood. 2011 Jan 13;117(2):429-39. doi: 10.1182/blood-2010-01-266833. Epub 2010 Sep 10.
8
CXCR4 and cancer.CXCR4 与癌症。
Pathol Int. 2010 Jul;60(7):497-505. doi: 10.1111/j.1440-1827.2010.02548.x.
9
Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.新型异喹啉 CXCR4 拮抗剂的合成及 SAR 研究及其具有很强的抗 HIV 活性。
Bioorg Med Chem Lett. 2010 May 15;20(10):3026-30. doi: 10.1016/j.bmcl.2010.03.118.
10
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.发现新型小分子、口服生物利用度的 C-X-C 趋化因子受体 4 拮抗剂，其为有效的 T 嗜性（X4）HIV-1 复制抑制剂。
J Med Chem. 2010 Apr 22;53(8):3376-88. doi: 10.1021/jm100073m.

基于具有改善类药性质的α-烷基哌嗪侧链的CXCR4拮抗剂的发现。

Discovery of -Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties.

作者信息

Tahirovic Yesim A, Truax Valarie M, Wilson Robert J, Jecs Edgars, Nguyen Huy H, Miller Eric J, Kim Michelle B, Kuo Katie M, Wang Tao, Sum Chi S, Cvijic Mary E, Schroeder Gretchen M, Wilson Lawrence J, Liotta Dennis C

机构信息

Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, United States.

Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States.

出版信息

ACS Med Chem Lett. 2018 Apr 9;9(5):446-451. doi: 10.1021/acsmedchemlett.8b00030. eCollection 2018 May 10.

DOI:10.1021/acsmedchemlett.8b00030
PMID:29795757
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5949813/
Abstract

A novel series of CXCR4 antagonists with piperidinyl and piperazinyl alkylamine side chains designed as butyl amine replacements are described. Several of these compounds showed similar activity to the parent compound TIQ-15 () in a SDF-1 induced calcium flux assay. Preliminary structure-activity relationship investigations led us to identify a series containing -propyl piperazine side chain analogs exemplified by with improved off-target effects as measured in a muscarinic acetylcholine receptor (mAChR) calcium flux assay and in a limited drug safety panel screen. Further efforts to explore SAR and optimize drug properties led to the identification of the '-ethyl--propyl-piperazine tetrahydroisoquinoline derivative and the -propyl-piperazine benzimidazole compound , which gave the best overall profiles with no mAChR or CYP450 inhibition, good permeability in PAMPA assays, and metabolic stability in human liver microsomes.

摘要

描述了一系列新型的CXCR4拮抗剂，其具有哌啶基和哌嗪基烷基胺侧链，设计用作丁胺替代物。在SDF-1诱导的钙流测定中，其中几种化合物显示出与母体化合物TIQ-15（）相似的活性。初步的构效关系研究使我们确定了一个含有丙基哌嗪侧链类似物的系列，以在毒蕈碱型乙酰胆碱受体（mAChR）钙流测定和有限的药物安全性面板筛选中测量的具有改善的脱靶效应为例。进一步探索构效关系和优化药物性质的努力导致鉴定出'-乙基 - 丙基 - 哌嗪四氢异喹啉衍生物和丙基 - 哌嗪苯并咪唑化合物，它们给出了最佳的总体概况，没有mAChR或CYP450抑制，在PAMPA测定中具有良好的渗透性，并且在人肝微粒体中具有代谢稳定性。